The PHARM Connect Congress 2011

9-10 February 2011, Budapest, Hungary.
The PHARM Connect Congress 2011, an event organised by The Events Group, offers the perfect setting for solution providers to present their products and services directly to key decision makers of target client population throughout Central & Eastern Europe.

Strictly operating on an invitation only basis guarantees that the highest level of delegation is present. Each solution provider at the PHARM Connect Congress is selected based on requirements and interests provided by attending Pharmaceutical professionals prior to the Congress event.

Over two days, service providers will meet and interact with the leading director and C level practitioners through a number of pre-arranged one-to-one business meetings and other networking activities.

Several weeks in advance of the Congress, the TEG Meeting Scheduler is made available to all solution providers and delegates attending. Participants receive individualized passwords to access the website where they are able to select key presentations, pre-schedule one-to-one meetings and confirm their presence at several additional networking activities. Through the Meeting Scheduler, attendees have the opportunity to create their own itinerary prior to the Congress taking place.

This networking event presents a unique opportunity to develop meaningful and valuable business relations.

For further information and registration, please visit:
http://www.pharmconnect.eu

About The Events Group
The Events Group is one of Europe's leading business information providers. With two main areas of focus, business-to-business Congresses and Professional Training, we primarily operate within key emerging markets: Central & Eastern Europe.

Our unique business-to-business Congresses bring together senior-level executives from Europe’s largest organisations with a select and diversified group of leading edge sponsors. Strictly operating on an invitation only basis guarantees that the highest level of delegation is present.

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...